共查询到20条相似文献,搜索用时 31 毫秒
1.
Atrial fibrillation with fast ventricular response remains a matter of concern in patients treated with an implantable cardioverter defibrillator (ICD). A patient with dilated cardiomyopathy, suffering from atrial arrhythmias and recurrent cardiac arrest due to both ventricular tachycardia and ventricular fibrillation, is presented. Ablation of the AV node by means of low-energy direct-current shocks with subsequent pacemaker implantation was performed before ICD implantation. The patient received shocks after four months, when he had recurrence of AV conduction with a slow ventricular rate. Pacemaker interaction was excluded, and no short ventricular arrhythmias were observed. During electrophysiologic study after electrical conversion of atrial fibrillation, persistent second degree heart block was documented, giving further evidence that atrial arrhythmias were not responsible for the shocks. The patient's functional status remains good after more than 18 months of follow-up. 相似文献
2.
The implantable cardioverter-defibrillator (ICD) is the standard of care in patients with ischemic and nonischemic cardiomyopathy who are at high risk for arrhythmic events and sudden cardiac death. Although an ICD saves life, ICD shocks are emotionally and physically debilitating. Most patients receive adjuvant antiarrhythmic drug therapy to circumvent episodes of recurrent ventricular and supraventricular arrhythmias. Antiarrhythmic drugs including b-blockers, sotalol, amiodarone, and azimilide are effective at reducing the shock burden. This article describes data supporting the need for and potential risks and benefits of adjuvant antiarrhythmic drug therapy and examines the benefits and pitfalls of the same in ICD-implanted patients. 相似文献
3.
《Revista portuguesa de cardiologia》2021,40(11):829-835
IntroductionVentricular arrhythmias are caused by scar tissue in patients with ischemic dilated cardiomyopathy. The gold standard imaging technique for detecting scar tissue is magnetic resonance imaging (MRI). However, MRI is not feasible for use as a screening test, and also cannot be used in patients who have received an implantable cardioverter-defibrillator (ICD). In this study, we aimed to assess the association between levels of galectin-3 (Gal-3), which is known to be secreted by scar tissue, and the history of ventricular arrhythmias in patients with ischemic dilated cardiomyopathy who received an ICD.MethodsNineteen healthy controls and 32 patients who had previously undergone VVI-ICD implantation due to ischemic dilated cardiomyopathy were enrolled in the study. Patients were divided into three groups: the first group including patients who had received no ICD therapies, the second including patients with arrhythmia requiring therapies with no arrhythmia storm, and the third including patients who had arrhythmia storm. We assessed the association between Gal-3 levels and the history of ventricular arrhythmias in these patients.ResultsGal-3 levels were significantly higher in the patient groups than in the control group (p<0.01). Gal-3 levels of patients with arrhythmias requiring ICD therapies were significantly higher than in patients with ICD not requiring therapies (p=0.02). They were also higher in patients with a history of arrhythmia storm than in patients without shocks (p=0.05). Receiver operating curve analysis showed with 84% sensitivity and 75% specificity that Gal-3 levels over 7 ng/ml indicated ventricular arrhythmia that required therapies.ConclusionGal-3 may be used to further improve risk stratification in patients with ischemic cardiomyopathy who are more prone to developing life-threatening arrhythmias. 相似文献
4.
Bharat K. Kantharia MD FRCP FAHA FACC FESC FHRS 《Journal of cardiovascular electrophysiology》2021,32(9):2558-2566
Implantable cardioverter defibrillators (ICDs) have proven to be life-saving devices in patients with ischemic cardiomyopathy (ICM) who are prone to develop ventricular tachycardia (VT) and fibrillation (VF). Antiarrhythmic drugs (AADs) are commonly prescribed in many such patients with ICDs to treat and prevent different forms of arrhythmias in clinical practice. When these patients experience recurrent monomorphic VT despite chronic AADs therapy, or when AAD therapy is contraindicated or not tolerated, and VT storm is refractory to AAD therapy, catheter ablation constitute guideline-based class I indication of treatment. However, what should be the most appropriate strategy to prevent first ICD shock or subsequent multiple shocks from VT/VF in patients with ICM who undergo ICD implantation without prior incidence of cardiac arrest, remains debatable. The purpose of this review is to discuss preventative aspects of ICD shocks for VT and the shortcomings of these measures along with the cost-effectiveness and global perspectives based on the current knowledge of the topic. 相似文献
5.
According to the current guidelines, patients with ischaemic cardiomyopathy (ICM) or non-ischaemic cardiomyopathy (NICM) at risk for sudden cardiac death should undergo implantation of an implantable cardioverter-defibrillator (ICD). Although ICDs effectively terminate ventricular arrhythmias, the arrhythmogenic substrate remains unchanged or may progress over time, resulting in recurrent ICD shocks. Defibrillator shocks increase mortality and worsen quality of life. Evidence from two prospective randomized trials on outcome in patients with ischaemic heart disease undergoing catheter ablation for ventricular tachycardia (VT) suggests that ablation prevents recurrence of VT and decreases the number of ICD shocks. This review will highlight the recent progress made in the ablative treatment of VT in patients with ICM and NICM. 相似文献
6.
ZALMEN BLANCK M.D. MICHAEL BIEHL M.D. JASBIR SRA M.D. ANWER DHALA M.D. MASOOD AKHTAR M.D. 《Journal of cardiovascular electrophysiology》1997,8(3):317-322
Shock Delivery Despite Abortive Shock Capability. Introduction: To describe the delivery of noncommitted implantable cardioverter defibrillator (ICD) shocks despite self-termination of ventricular arrhythmias. Abortive shock capability should eliminate the delivery of shocks for self-terminating ventricular arrhythmias. The delivery of noncommitted shocks despite abortive shock capability is, therefore, unexpected and previously unreported.
Methods and Results: Among 118 patients who received the Transvene nonthoracotomy lead system and the Jewel ICD (model 7219D), three patients (1.7%) experienced spurious, noncommitted shocks for self-terminating arrhythmias. Only one detection zone (i.e., ventricular fibrillation) had been programmed in the defibrillator in each patient. In all three patients, the ventricular arrhythmias self-terminated during the charging period. One patient received seven shocks during periods of asystole, and the other two patients received one shock each. Two different mechanisms for shock delivery in this setting were identified: one occurring in the absence of electrical activity at the end of the bradycardia escape interval (i.e., associated with bradyarrhytbmias), and the other when two sensed electrical events (i.e., escape beats) occurred during the so-called "synchronization" window of the defibrillator.
Conclusions: In rare patients with the Jewel defibrillator, shocks may be delivered for self-terminating arrhythmias despite abortive shock capability. Patients who are dependent upon pacing from their implanted defibrillator are at particular risk for shock in the aftermath of self-terminating ventricular arrhythmias. Defibrillator programming strategies aimed at eliminating or diminishing the incidence of this problem are discussed. 相似文献
Methods and Results: Among 118 patients who received the Transvene nonthoracotomy lead system and the Jewel ICD (model 7219D), three patients (1.7%) experienced spurious, noncommitted shocks for self-terminating arrhythmias. Only one detection zone (i.e., ventricular fibrillation) had been programmed in the defibrillator in each patient. In all three patients, the ventricular arrhythmias self-terminated during the charging period. One patient received seven shocks during periods of asystole, and the other two patients received one shock each. Two different mechanisms for shock delivery in this setting were identified: one occurring in the absence of electrical activity at the end of the bradycardia escape interval (i.e., associated with bradyarrhytbmias), and the other when two sensed electrical events (i.e., escape beats) occurred during the so-called "synchronization" window of the defibrillator.
Conclusions: In rare patients with the Jewel defibrillator, shocks may be delivered for self-terminating arrhythmias despite abortive shock capability. Patients who are dependent upon pacing from their implanted defibrillator are at particular risk for shock in the aftermath of self-terminating ventricular arrhythmias. Defibrillator programming strategies aimed at eliminating or diminishing the incidence of this problem are discussed. 相似文献
7.
Simon Abou Jaoudé Elie Salamé Rabih Azar Roland Kassab 《Journal of interventional cardiac electrophysiology》2003,9(3):401-403
Implantable cardioverter-defibrillator (ICD) is highly effective in treating life-threatening ventricular arrhythmias, but it can also have proarrhythmic effect in some cases. We report the case of a 72 years old patient with an ischemic cardiomyopathy in whom an ICD was implanted for a poorly tolerated ventricular tachycardia (Profiles MD—Ventritex). Forty-eight hours after implantation, the patient suddenly received 15 successive shocks. ECG tracings and intracardiac EGM showed the presence of several VT episodes, all induced by the antibradycardia pacing of the ICD: the automatic gain control function of the device failed to detect ventricular premature beats in this patient, leading to a bradycardia pacing falling on the T wave and inducing multiple VTs and shocks. 相似文献
8.
Barsheshet A Goldenberg I Moss AJ Huang DT Zareba W McNitt S Klein HU Guetta V 《Journal of cardiovascular electrophysiology》2011,22(11):1237-1242
Coronary Revascularization and Long‐Term Mortality in MADIT‐II. Introduction: Coronary revascularization (CR) may reduce arrhythmia risk and improve long‐term outcome in patients with left ventricular dysfunction. This study was designed to evaluate the effect of elapsed time from CR on long‐term mortality and arrhythmic risk among patients who receive an implantable cardioverter defibrillator (ICD). Methods and Results: We evaluated the risk of 8‐year mortality by elapsed time from CR to ICD implantation (categorized as: no CR; recent CR [<2 years]; or nonrecent CR [≥2 years], and assessed as a continuous measure) among 720 ICD recipients enrolled in the Multicenter Automatic Defibrillator Trial‐II. At 8years of follow‐up, patients who did not undergo CR and those who underwent nonrecent CR had significantly higher mortality rates than patients who underwent recent CR (54%, 54%, and 36%, respectively; P < 0.001). Multivariate analysis demonstrated that no‐ and nonrecent CR were associated with respective 48% (P = 0.022) and 67% (P < 0.001) increases in mortality risk compared with recent CR. Assessment of time from CR as a continuous measure showed that every year elapsed from CR was associated with an adjusted 6% increase in 8‐year mortality (P < 0.001), and in respective 6% (P < 0.001) and 6% (P = 0.003) increased risk for in‐trial appropriate ICD therapy of ventricular tachyarrhythmias and appropriate ICD shocks. Conclusions: We observed a direct relationship between elapsed time from CR and long‐term mortality following ICD implantation. The favorable long‐term effect on outcome of recent CR may be related to a time‐dependent effect of CR on ventricular arrhythmic burden and the need for appropriate ICD shocks. (J Cardiovasc Electrophysiol, Vol. pp. 1‐6) 相似文献
9.
Matthews JC Betley D Morady F Pelosi F 《Journal of cardiovascular electrophysiology》2007,18(10):1107-1108
An increasing number of patients have a coexisting implantable cardioverter defibrillator (ICD) and left ventricular assist device (LVAD) to treat ventricular arrhythmias and refractory heart failure, respectively. To date, there have been no published reports of negative interactions between these devices that have impacted appropriate ICD or LVAD function. In this case report, we describe a patient with an LVAD-ICD interaction that necessitated replacement of the implantable defibrillator. 相似文献
10.
Adults with congenital heart disease are at risk of lethal ventricular arrhythmias and are candidates for implantable cardiac defibrillator (ICD) therapy, yet implant risks, long-term outcomes, and rates of appropriate and inappropriate ICD therapies are not well characterized. We reviewed clinical, implantation, and follow-up data on all transvenous ICDs in adults with congenital heart disease at the Mayo Clinic from 1991 through 2008. Seventy-three adults with congenital heart disease received 85 ICDs. Implantation diagnoses included tetralogy of Fallot (44%) and congenitally corrected transposition of the great arteries (17%). Implantation indication was occurrence of sustained ventricular arrhythmias (secondary prevention) in 36% and prophylactic (primary prevention) in the remainder. There were no major implant-related complications. During follow-up (2.2 ± 2.8 years, range 0 to 15) 11 patients died and 4 patients received heart or heart/lung transplants. An appropriate shock for a ventricular arrhythmia was observed in 19% of patients and an inappropriate shock was observed in 15% of patients. Likelihood of an appropriate shock was associated with increased subpulmonic ventricular pressure. In conclusion, implantation of transvenous ICDs in adults with congenital heart disease is associated with a low risk of implant complications. In this high-risk adult population the rate of inappropriate ICD shocks is low, whereas the likelihood of appropriate therapy for potentially lethal ventricular arrhythmias is high. These data suggest overall benefit of ICD therapy in adults with congenital heart disease. 相似文献
11.
Controlled clinical trials provide incontrovertible evidence that implantable cardioverter defibrillators (ICDs) are effective
to reduce risk of death in select patients with ischemia or nonischemic cardiomyopathy and/or malignant ventricular arrhythmias.
Although indications for ICDs have expanded, few data are available regarding their use in the elderly and extreme elderly
patients. As increasing numbers of patients become eligible for ICD implantation, questions arise regarding the benefit of
ICDs in the elderly, in whom risk of death from comorbidities and nonarrhythmic cardiovascular causes is higher. Although
guidelines support ICD implantation in appropriately selected elderly patients, the proper selection of patients remains controversial.
Those elderly patients with multiple comorbidities and limited life expectancy may not be appropriate candidates for ICD implantation,
even if they meet standard guidelines. Decisions must be individualized and based on clinical judgment, careful understanding
of the risks and benefits of an ICD, and preferences of the patient and the family. 相似文献
12.
Li CH Lin YJ Huang JL Wu TJ Cheng CC Lin WS Tuan TC Chang SL Lo LW Hu YF Chao TF Chung FP Tsai CF Tsao HM Chen SA 《Journal of cardiovascular electrophysiology》2012,23(7):750-756
Long‐Term Prognosis in Patients with ARVC. Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a major cause of sudden cardiac death due to tachyarrhythmias. The purpose of this study was to investigate the long‐term prognosis in patients with ARVC and the incidence of rapid ventricular arrhythmias during follow‐up. Methods: Thirty ARVC patients (19 male, 63.3%, mean age 48 ± 15 years) fulfilling modified Task Force criteria 2010 were included. Of them, 13 patients (43.3%) received implantable cardioverter‐defibrillator (ICD) implantation. Rapid ventricular arrhythmia was defined as electrical storm or the occurrence of ventricular tachycardia (VT) or ventricular fibrillation (VF) with a cycle length of 240 ms or less that necessitate shock delivery to 2 or more times within a 24‐hour period. Results: With a mean follow‐up of 68 ± 10 months, 6 patients (20%) with ICD implantation had recurrent rapid VT/VF. One (3.3%) of them died of multiple shocks and SCD, and 5 (16.7%) had multiple ICD therapies due to VT/VF and electrical storm. The interval between the diagnosis of ARVC and occurrence of rapid VT/VF was 13.4 ± 4.9 months. Most (5/6, 83.3%) events of recurrent rapid VT/VF occurred within 2 years. Ablated patients who did not receive an ICD implant were totally free of rapid VT/VF. Conclusions: For patients with ARVC, long‐term prognosis is favorable. During a long‐term follow‐up, patients meeting the criteria for ICD implantation have a higher rate of rapid and potentially life‐threatening arrhythmias. However, early and clustered recurrence of rapid VT/VF in patients with an ICD is common, whereas late occurrence of rapid VT/VF is very rare. (J Cardiovasc Electrophysiol, Vol. 23, pp. 750‐756, July 2012) 相似文献
13.
Wolfram Grimm Ulrike Steder Volker Menz Bernhard Maisch 《Annals of noninvasive electrocardiology》1996,1(4):419-422
Background: QT dispersion, measured as interlead variability of QT intervals in the surface electrocardiogram, has been demonstrated to provide an indirect measurement of the inhomogeneity of myocardial repolarization as a potential substrate for ventricular arrhythmias. Methods: QT dispersion was measured in the standard 12-lead ECG in 51 patients at the time of implantation of a third generation implantable cardioverter defibrillator (ICD) with automatic electrogram storage capability for electrical events triggering device therapy. In addition, QT dispersion was measured in 100 age- and sex-matched healthy controls. All 5 1 study patients with ICD were prospectively followed to determine possible associations between QT dispersion at implant and subsequent spontaneous ICD shocks for ventricular tachyarrhythmias (VT). Results: Rate-corrected QT dispersion and adjusted QTc dispersion, which takes account of the number of leads measured, were significantly greater in ICD patients compared to controls (76 ± 25 ms vs 46 ± 11 ms, and 24 ± 7 ms vs 14 ± 3 ms respectively, P < 0.0 1). During 15 ± 8 months follow-up, ventricular tachyarrhythmias occurred in 23 (45%) of 51 ICD patients. QTc dispersion and adjusted QTc dispersion were not significantly different between ICD patients with ventricular tachyarrhythmias and ICD patients without ventricular tachyarrhythmias during follow-up (74 ± 19 ms versus 77 ± 29 ms, and 23 ± 6 ms vs 25 ± 8 ms respectively). Conclusion: Increased QT dispersion measured in the 12-lead standard ECG does not appear to be a useful marker for future arrhythmic events in a mixed patient population with ICD. 相似文献
14.
M. Cecilia Gonzalez Corcia Juan Sieira Gudrun Pappaert Carlo de Asmundis Gian Battista Chierchia Mark La Meir Andrea Sarkozy Pedro Brugada 《Journal of the American College of Cardiology》2018,71(2):148-157
Background
Young patients presenting with symptomatic Brugada syndrome have very high risks for ventricular arrhythmias and should be carefully considered for implantable cardioverter-defibrillator (ICD) placement. However, this therapy is associated with high rates of inappropriate shocks and device-related complications.Objectives
This study investigated clinical features, management, and long-term follow-up of young patients with Brugada syndrome and ICD.Methods
Patients diagnosed with Brugada syndrome, who underwent implantation of an ICD at an age of ≤20 years, were studied.Results
The study included 35 consecutive patients. The mean age at ICD placement was 13.9 ± 6.2 years. Ninety-two percent were symptomatic; 29% presented with aborted sudden cardiac death and 63% with syncope. During a mean follow-up period of 88 months, sustained ventricular arrhythmias were treated by the ICD in 9 patients (26%), including shocks in 8 patients (23%) and antitachycardia pacing in 1 patient (3%). Three patients (9%) died in an electrical storm. Seven patients (20%) experienced inappropriate shocks, and 5 patients (14%) had device-related complications. Aborted sudden cardiac death and spontaneous type I electrocardiogram were identified as independent predictors of appropriate shock occurrence.Conclusions
ICD therapy is an effective strategy in young patients with symptomatic Brugada syndrome, treating potentially lethal arrhythmias in >25% of patients during follow-up. Appropriate shocks were significantly associated with previously aborted sudden cardiac death and spontaneous type I electrocardiograms. However, ICDs are frequently associated with complications and inappropriate shocks, both of which remain high regardless of careful device implantation and programming. 相似文献15.
目的 植入型心律转复除颤器(ICD)是恶性室性心律失常患者惟一有效的治疗措施。不适当识别和治疗是ICD最常见的并发症,也是导致ICD患者再住院最主要的原因。本文旨在评价本中心的ICD患者不适当识别和治疗的发生率及常见原因。方法 入选2000年1月至2005年12月在本中心因室性心律失常植入ICD并能定期随访的50例患者。根据患者心律失常特点和心功能情况程控ICD的各项参数,定期随访,询问ICD中所有信息,打印、存盘并对储存的腔内电图进行逐条分析,以确定ICD诊断是否准确以及治疗是否有效,判断有无ICD不适当识别和治疗。结果 38例患者在随访期间发生了心律失常事件,ICD共记录到491次室性心动过速(VT)或心室颤动(VF)事件(VT383次,VF108次),其中有11例(22%)发生过≥1次的不适当识别和治疗事件。14.3%(55/383)的VT事件为不适当识别,并导致了78次抗心动过速起搏(ATP)治疗和9次电击治疗。VF不适当识别的发生率为26.9%(28/108),并导致了56次不适当电击事件。结论 植入新一代ICD患者中,不适当识别和治疗发生率仍较高。不适当识别和治疗最常见的原因是心房颤动(房颤)伴快速心室率,占50%以上;其次是由于电磁干扰或肌电干扰所致。 相似文献
16.
PD Dr. C.W. Israel 《Herzschrittmachertherapie & Elektrophysiologie》2010,21(2):102-108
ICD therapy represents a major advance in the treatment of patients with severely impaired left ventricular function after myocardial infarction. While an ICD implantation also remains a valuable option late (>5 years) after myocardial infarction, patients early after this event are at a competitive risk of arrhythmogenic and nonarrhythmogenic cardiac death. Prevention of sudden cardiac death in patients early after myocardial infarction, therefore, just converts the mode of death in a significant number of patients from sudden to nonsudden cardiac death (conversion theory). In patients with a left ventricular ejection fraction (LVEF) of ≤30% after myocardial infarction, implantation of the ICD should, therefore, be postponed to at least 30–40 days after the event. It is, however, not clear how the risk of sudden cardiac death should be approached during this post infarction phase. Similarly, it is not clear if patients with a reduced LVEF post infarction and additional specific risks (nonsustained ventricular tachycardia, atrial fibrillation, bundle branch block, etc.) beyond this single criterion may also benefit from ICD implantation and which risk factors may be relevant. In any case, ICD therapy should avoid right ventricular pacing and shock discharges whenever possible. 相似文献
17.
David T. Huang MD Igor Gosev MD PhD Katherine L. Wood MD Hima Vidula MD William Stevenson MD Frank Marchlinski MD Gregory Supple MD Sandip K. Zalawadiya MD J. Peter Weiss MD Roderick Tung MD Wendy S. Tzou MD Joshua D. Moss MD Krishna Kancharla MD Sunit-Preet Chaudhry MD Parin J. Patel MD Arfaat M. Khan MD Claudio Schuger MD Guy Rozen MD Michael S. Kiernan MD Gregory S. Couper MD Marzia Leacche MD Ezequiel J. Molina MD Anand D. Shah MD Michael Lloyd MD Jakub Sroubek MD PhD Edward Soltesz MD Kalyanam Shivkumar MD PhD Casey White MD Sinan Tankut MD Brent A. Johnson PhD Scott McNitt MS Valentina Kutyifa MD PhD Wojciech Zareba MD PhD Ilan Goldenberg MD 《Annals of noninvasive electrocardiology》2023,28(5):e13073
Background
The use of a Left Ventricular Assist Device (LVAD) in patients with advanced heart failure refractory to optimal medical management has progressed steadily over the past two decades. Data have demonstrated reduced LVAD efficacy, worse clinical outcome, and higher mortality for patients who experience significant ventricular tachyarrhythmia (VTA). We hypothesize that a novel prophylactic intra-operative VTA ablation protocol at the time of LVAD implantation may reduce the recurrent VTA and adverse events postimplant.Methods
We designed a prospective, multicenter, open-label, randomized-controlled clinical trial enrolling 100 patients who are LVAD candidates with a history of VTA in the previous 5 years. Enrolled patients will be randomized in a 1:1 fashion to intra-operative VTA ablation (n = 50) versus conventional medical management (n = 50) with LVAD implant. Arrhythmia outcomes data will be captured by an implantable cardioverter defibrillator (ICD) to monitor VTA events, with a uniform ICD programming protocol. Patients will be followed prospectively over a mean of 18 months (with a minimum of 9 months) after LVAD implantation to evaluate recurrent VTA, adverse events, and procedural outcomes. Secondary endpoints include right heart function/hemodynamics, healthcare utilization, and quality of life.Conclusion
The primary aim of this first-ever randomized trial is to assess the efficacy of intra-operative ablation during LVAD surgery in reducing VTA recurrence and improving clinical outcomes for patients with a history of VTA. 相似文献18.
Karim Benali MD Michael S. Lloyd MD Andranik Petrosyan MD PhD Louis Rigal MD Magali Quivrin MD Igor Bessieres MD PhD Konstantinos Vlachos MD Nefissa Hammache MD Julien Bellec MD PhD Antoine Simon MD PhD Gabriel Laurent MD PhD Kristin Higgins Fabien Garnier MD Renaud de Crevoisier MD PhD Raphaël Martins MD PhD Antoine Da Costa MD PhD Charles Guenancia MD PhD 《Journal of cardiovascular electrophysiology》2024,35(1):206-213
Left ventricular assist device (LVAD) implantation is an established treatment for patients with advanced heart failure refractory to medical therapy. However, the incidence of ventricular arrhythmias (VAs) is high in this population, both in the acute and delayed phases after implantation. About one-third of patients implanted with an LVAD will experience sustained VAs, predisposing these patients to worse outcomes and complicating patient management. The combination of pre-existing myocardial substrate and complex electrical remodeling after LVAD implantation account for the high incidence of VAs observed in this population. LVAD patients presenting VAs refractory to antiarrhythmic therapy and catheter ablation procedures are not rare. In such patients, treatment options are extremely limited. Stereotactic body radiation therapy (SBRT) is a technique that delivers precise and high doses of radiation to highly defined targets, reducing exposure to adjacent normal tissue. Cardiac SBRT has recently emerged as a promising alternative with a growing number of case series reporting the effectiveness of the technique in reducing the VA burden in patients with arrhythmias refractory to conventional therapies. The safety profile of cardiac SBRT also appears favorable, even though the current clinical experience remains limited. The use of cardiac SBRT for the treatment of refractory VAs in patients implanted with an LVAD are even more scarce. This review summarizes the clinical experience of cardiac SBRT in LVAD patients and describes technical considerations related to the implementation of the SBRT procedure in the presence of an LVAD. 相似文献
19.
Refaat MM Tanaka T Kormos RL McNamara D Teuteberg J Winowich S London B Simon MA 《Journal of cardiac failure》2012,18(2):140-145
BackgroundImplantable cardioverter-defibrillators (ICDs) reduce mortality in heart failure (HF). In patients requiring a ventricular assist device (VAD), the benefit from ICD therapy is not well established. The aim of this study was to define the impact of ICD on outcomes in VAD-supported patients.Methods and ResultsWe reviewed data for consecutive adult HF patients receiving VAD as a bridge to transplantation from 1996 to 2003. The primary outcome was survival to transplantation. A total of 144 VADs were implanted [85 left ventricular (LVAD), 59 biventricular (BIVAD), mean age 50 ± 12 years, 77% male, left ventricular ejection fraction 18 ± 9%, 54% ischemic]. Mean length of support was 119 days (range 1–670); 103 patients (72%) survived to transplantation. Forty-five patients had an ICD (33 LVAD, 12 BIVAD). More LVAD patients had an appropriate ICD shock before implantation than after (16 vs 7; P = .02). There was a trend toward higher shock frequency before LVAD implant than after (3.3 ± 5.2 vs 1.1 ± 3.8 shocks/y; P = .06). Mean time to first shock after VAD implant was 129 ± 109 days. LVAD-supported patients with an ICD were significantly more likely to survive to transplantation [1-y actuarial survival to transplantation: LVAD: 91% with ICD vs 57% without ICD (log-rank P = .01); BIVAD: 54% vs 47% (log-rank P = NS)]. An ICD was associated with significantly increased survival in a multivariate model controlling for confounding variables (odds ratio 2.54, 95% confidence interval 1.04–6.21; P = .04).ConclusionsShock frequency decreases after VAD implantation, likely owing to ventricular unloading, but appropriate ICD shocks still occur in 21% of patients. An ICD is associated with improved survival in LVAD-supported HF patients. 相似文献
20.
Mark S. Link Douglas Laidlaw Bronislava Polonsky Wojciech Zareba Scott McNitt Kathleen Gear Frank Marcus N. A. Mark Estes III 《Journal of the American College of Cardiology》2014